ArticleEJHaem2023

Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.

Reem Karmali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.